FULCRUM THERAPEUTICS, INC. (FULC) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -96.05M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 56.24M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-96.05M | (m) | (m) | $56.24M | (m) | (m) |
| 2026-03-31 | $-86.55M | (m) | (m) | $56.78M | (m) | (m) |
| 2025-12-31 | $-84.77M | (m) | (m) | $56.10M | (m) | (m) |
| 2025-09-30 | $-81.50M | (m) | (m) | $52.40M | (m) | (m) |
| 2025-06-30 | $-84.77M | (m) | (m) | $52.74M | (m) | (m) |
| 2025-03-31 | $-12.47M | (m) | (m) | $57.02M | (m) | (m) |
| 2024-12-31 | $-21.90M | (m) | (m) | $63.39M | (m) | (m) |
| 2024-09-30 | $-30.46M | (m) | (m) | $70.67M | (m) | (m) |
| 2024-06-30 | $-32.77M | (m) | (m) | $74.27M | (m) | (m) |
| 2024-03-31 | $-112.56M | (m) | (m) | $74.86M | (m) | (m) |
| 2023-12-31 | $-110.66M | (m) | (m) | $71.80M | (m) | (m) |
| 2023-09-30 | $-110.64M | (m) | (m) | $71.37M | (m) | (m) |
| 2023-06-30 | $-107.56M | (m) | (m) | $68.50M | (m) | (m) |
| 2023-03-31 | $-114.50M | (m) | (m) | $75.67M | (m) | (m) |
| 2022-12-31 | $-112.56M | (m) | (m) | $76.78M | (m) | (m) |
| 2022-09-30 | $-108.15M | (m) | (m) | $77.13M | (m) | (m) |
| 2022-06-30 | $-104.56M | (m) | (m) | $78.84M | (m) | (m) |
| 2022-03-31 | $-90.01M | (m) | (m) | $71.20M | (m) | (m) |
| 2021-12-31 | $-81.05M | (m) | (m) | $69.70M | (m) | (m) |
| 2021-09-30 | $-75.28M | (m) | (m) | $66.93M | (m) | (m) |
| 2021-06-30 | $-73.62M | (m) | (m) | $65.50M | (m) | (m) |
| 2021-03-31 | $-69.86M | (m) | (m) | $60.89M | (m) | (m) |
| 2020-12-31 | $-71.61M | (m) | (m) | $59.04M | (m) | (m) |
| 2020-09-30 | $-70.31M | (m) | (m) | $54.98M | (m) | (m) |
| 2020-06-30 | $-68.22M | (m) | (m) | $52.84M | (m) | (m) |
| 2020-03-31 | $-65.79M | (m) | (m) | $50.92M | (m) | (m) |
| 2019-12-31 | $-84.22M | (m) | (m) | $71.07M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-33.50M | (m) | (m) | $25.18M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |